Trials / Unknown
UnknownNCT03071926
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients With Primary Endocrine Resistant Advanced Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Metronomic PLD in Patients with Primary Endocrine Resistant ABC
Detailed description
Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients with Primary Endocrine Resistant Advanced Breast Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Liposomal Doxorubicin | 20 mg, qw, first 6 weeks ,every 8 weeks |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2017-03-07
- Last updated
- 2022-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03071926. Inclusion in this directory is not an endorsement.